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Mutations in GMPPB cause congenital
myasthenic syndrome and bridge myasthenic
disorders with dystroglycanopathies
Katsiaryna Belaya,1 Pedro M. Rodrı´guez Cruz,1,2 Wei Wei Liu,1 Susan Maxwell,1
Simon McGowan,3 Maria E. Farrugia,4 Richard Petty,4 Timothy J. Walls,5 Maryam Sedghi,6
Keivan Basiri,7 Wyatt W. Yue,8 Anna Sarkozy,9,10 Marta Bertoli,9 Matthew Pitt,11
Robin Kennett,2 Andrew Schaefer,5 Kate Bushby,9 Matt Parton,10 Hanns Lochmu¨ller,9
Jacqueline Palace,2 Francesco Muntoni12 and David Beeson1
Congenital myasthenic syndromes are inherited disorders that arise from impaired signal transmission at the neuromuscular
junction. Mutations in at least 20 genes are known to lead to the onset of these conditions. Four of these, ALG2, ALG14,
DPAGT1 and GFPT1, are involved in glycosylation. Here we identify a fifth glycosylation gene, GMPPB, where mutations
cause congenital myasthenic syndrome. First, we identified recessive mutations in seven cases from five kinships defined as con-
genital myasthenic syndrome using decrement of compound muscle action potentials on repetitive nerve stimulation on electro-
myography. The mutations were present through the length of the GMPPB, and segregation, in silico analysis, exon trapping, cell
transfection followed by western blots and immunostaining were used to determine pathogenicity. GMPPB congenital myasthenic
syndrome cases show clinical features characteristic of congenital myasthenic syndrome subtypes that are due to defective glyco-
sylation, with variable weakness of proximal limb muscle groups while facial and eye muscles are largely spared. However, patients
with GMPPB congenital myasthenic syndrome had more prominent myopathic features that were detectable on muscle biopsies,
electromyography, muscle magnetic resonance imaging, and through elevated serum creatine kinase levels. Mutations in GMPPB
have recently been reported to lead to the onset of muscular dystrophy dystroglycanopathy. Analysis of four additional GMPPB-
associated muscular dystrophy dystroglycanopathy cases by electromyography found that a defective neuromuscular junction
component is not always present. Thus, we find mutations in GMPPB can lead to a wide spectrum of clinical features where
deficit in neuromuscular transmission is the major component in a subset of cases. Clinical recognition of GMPPB-associated
congenital myasthenic syndrome may be complicated by the presence of myopathic features, but correct diagnosis is important
because affected individuals can respond to appropriate treatments.
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Introduction
Congenital myasthenic syndromes (CMS) are a rare and
heterogeneous group of inherited disorders caused by mu-
tations in genes encoding proteins that are essential for
neuromuscular transmission. All CMS share the clinical
feature of fatigable weakness, but age at onset, presenting
symptoms, distribution of weakness, and response to treat-
ment differ depending on the molecular mechanism that
results from the genetic defect (Engel, 2012; Cruz et al.,
2014). In most cases impaired transmission can be detected
by EMG, and a decrement in the amplitude of compound
muscle action potentials in response to repetitive nerve
stimulation and/or increased jitter represent crucial diag-
nostic criteria for these disorders. Mutations in at least
20 different genes are known to lead to the development
of CMS (Cruz et al., 2014). Four of these, ALG2, ALG14,
DPAGT1 and GFPT1, are recently identified genes encod-
ing proteins involved in glycosylation (Fig. 1) (Senderek
et al., 2011; Belaya et al., 2012; Cossins et al., 2013).
ALG2, ALG14 and DPAGT1 are involved specifically in
N-linked protein glycosylation. GFPT1 is involved in the
synthesis of UDP-GlcNAc, a nucleotide sugar used as a
building block by several glycosylation pathways, including
N- and O-linked glycosylation. These four subtypes of gly-
cosylation-CMS have characteristic clinical features that
help to distinguish them from other CMS subtypes. The
most commonly affected muscles are proximal limb mus-
cles, with limited ocular or facial involvement. Identified
cases may respond to treatment with pyridostigmine or a
combination of pyridostigmine and salbutamol. The patho-
genic mechanism of these disorders is not entirely under-
stood, but it has been proposed that one contributing
pathogenic molecular mechanism underlying the disorders
is due to the abnormal glycosylation of acetylcholine recep-
tor (AChR) subunits (Belaya et al., 2012; Cossins et al.,
2013; Zoltowska et al., 2013). Glycosylation of AChRs is
required for assembly of AChR pentamers and for efficient
export of the receptors to the cell surface (Nomoto et al.,
1986; Gehle and Sumikawa, 1991; Gehle et al., 1997;
Wanamaker et al., 2003). Disruption of glycosylation
leads to a lack of AChRs at the endplate region, and a
reduced synaptic response to acetylcholine. Other neuro-
muscular junction proteins are likely to be affected by ab-
normal glycosylation and might further contribute to the
phenotype (Selcen et al., 2014).
There remain a number of CMS cases that have a clear
neuromuscular transmission defect, but no identified muta-
tion in the known CMS-associated genes. Here, we use
whole exome sequencing to identify CMS-causing muta-
tions in GDP-mannose pyrophosphorylase B (GMPPB).
Mutations in GMPPB have been previously associated
with the development of a muscular dystrophy dystrogly-
canopathy (MDDG), which is caused by the defective O-
glycosylation of -dystroglycan (Carss et al., 2013).
GMPPB-MDDG patients present with a characteristic
set of dystrophic features, which are often accompanied
by a variable degree of structural brain and eye abnormal-
ities. We identify a spectrum of clinical phenotypes asso-
ciated with GMPPB mutations that stretched from
defective neuromuscular transmission forming the major
symptomatic component to GMPPB-MDDG cases
in which there is no detectable neuromuscular junction
defect.
Materials and methods
Patient data
Patient consent for use of data was obtained with ethical ap-
proval OXREC B: 04.OXB.017 and Oxfordshire REC C 09/
H0606/74. Patient neurophysiology, muscle MRI, and serum
creatine kinase levels were measured by standard clinical
techniques.
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Whole exome sequencing
Patient genomic DNA was extracted from peripheral
blood using Nucleon kit (Gen-Probe Life Sciences Ltd).
Exome library was captured from 3mg of genomic DNA
using Agilent SureSelect XT Human All Exon v.4 kit. The
libraries were sequenced by 100 nt paired-end reads on
Illumina HiSeq platform. The obtained sequences were
mapped to human genome build hg19 by using Novoalign
software (Novocraft Technologies). Variants were called
using Samtools program (Li et al., 2009). Variants were fil-
tered out if their population frequency was 50.01 according
to 1000 Genomes Project (European subset) (Genomes
Project et al., 2010). We used ANNOVAR software to
annotate and separate non-synonymous substitutions, indel
variants and splicing mutations (Wang et al., 2010). As
CMS are usually inherited in an autosomal recessive manner,
we focused on all genes that have either one or more homo-
zygous variant, or two or more heterozygous variants in the
same gene. We further filtered the obtained variants against an
in-house database of 14 exomes from cases with unrelated
disorders, and manually removed misaligned or low quality
reads.
Analysis of GMPPB expression and
localization
IMAGE clone containing cDNA of GMPPB was purchased
from Source Bioscience Lifesciences (IRAUp969D1013D).
GMPPB coding sequence was subcloned into the mammalian
expression vector pcDNA3.1-hygro (Invitrogen). Mutations
were introduced using site-directed mutagenesis using
QuikChange kit from Stratagene. All sequences were con-
firmed by Sanger sequencing. HEK293 cells were transfected
with wild-type or mutant constructs. Forty-eight hours after
transfection, the cells were harvested and lysed by rotating in
cold lysis buffer [10mM Tris (pH 7.5), 100mM NaCl, 1mM
EDTA, 1% TritonTM X-100, mammalian protease inhibitor
cocktail form Sigma] for 1 h. Cell extracts were centrifuged
and resuspended into protein loading buffer. Protein extracts
were separated by sodium dodecyl sulphate polyacrylamide gel
electrophoresis and transferred onto polyvinylidene difluoride
membrane. The membrane was incubated with primary anti-
GMPPB antibody (Abcam ab154061) and secondary anti-
rabbit antibody conjugated to horseradish peroxidase
(Dako). Detection was performed by using ECL (GE
Healthcare).
For the analysis of GMPPB localization, C2C12 muscle cells
were transfected with wild-type or mutant GMPPB constructs
using the Neon Transfection System (Life Technologies).
Transfection was performed according to manufacturer’s rec-
ommendations using 2mg of each DNA construct. The cells
were fixed 24 h after electroporation. Fixed cells were permea-
bilized using 0.1% Triton in phosphate-buffered saline,
blocked in 1% bovine serum albumin, stained with primary
anti-GMPPB antibody and secondary anti-rabbit antibody con-
jugated to Alexa Fluor 488 (Invitrogen). Imaging was per-
formed on the inverted Zeiss LSM 510 META confocal
microscope.
Exon trapping
We cloned GMPPB exons 2, 3, 4 and flanking intronic se-
quences into the pET01 vector (MoBiTec). The c.130-3C4G
mutation was introduced by site-directed mutagenesis using
QuikChange kit from Stratagene and confirmed by Sanger
sequencing. Control and mutant vector DNA were electropo-
rated into the human rhabdomyosarcoma cell line TE671
using the Neon electroporator (Invitrogen). Total RNA was
purified 48 h after transfection, reverse transcribed into cDNA
using RETROscript kit (Ambion). Complementary DNA was
amplified using primers specific to the vector exons. The ampli-
cons were run on agarose/TBE (Tris-borate-EDTA) gels, visua-
lized under UV/ethidium bromide and then gel purified and
sequenced.
Figure 1 Simplified scheme of N-linked and O-linked glycosylation. The scheme shows five glycosylation genes associated with CMS.
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Results
Clinical features
Cases 1–7
Cases 1–7 demonstrate the hallmarks of myasthenic dis-
orders with fluctuating fatigable muscle weakness and
clear decrement of compound muscle action potential on
EMG during repetitive nerve stimulation (Table 1 and
Fig. 2). Cases 1, 2, 3 and 7 are unrelated individuals of
Caucasian descent. Cases 4, 5 and 6 are siblings from a
consanguineous marriage of first cousins once removed
(of Iranian origin). Typically, presentation was in adoles-
cence or adulthood and included limited march tolerance,
inability to run and lift weights, and difficulties in rising
from the floor. In retrospect the onset of muscle weakness
may be earlier because the majority of cases recall being
slower than their peers at school, not excelling in sports,
and some delay of motor milestones. Muscle weakness was
found to be most prominent in proximal limb muscles,
while facial, eye, and bulbar muscles are largely spared.
Ptosis is only present in Case 4. The patients reported ac-
tivity-dependent fatigability and improvement with rest. In
addition, they also presented fluctuations of muscle strength
over time, from days to weeks or even months. On occa-
sions, deteriorations have followed recognizable precipi-
tants such as viral infections or menstruation but they
have also occurred spontaneously. As an example, Case 1
had fluctuations of muscle strength over the course of
weeks. At best she is able to walk short distances
(20m) using a walking aid. At worst, she cannot walk
at all, is wheelchair bound and needs assistance to stand or
transfer. Where tried, patients responded to a treatment
with pyridostigmine or a combination of pyridostigmine
and salbutamol. Patients reported increased power of prox-
imal muscles and increased tolerance to walking and climb-
ing stairs. Neurophysiological abnormalities were
consistently found in all cases (Table 1). Of note, not all
muscle groups showed neuromuscular junction dysfunction
on electromyography. For example, Case 3 had significant
decrement (50%) on repetitive nerve stimulation of anco-
neus muscle but no decrement was detected in abductor
digiti minimi (Fig. 2). Similarly, Case 7 had a significant
decrement (23–30%) in trapezius muscle, whereas there
was no observable decrement when performing repetitive
nerve stimulation on abductor digiti minimi. These record-
ings were consistent with the pattern of muscle weakness
observed in the affected individuals. Unusual for CMS,
where tested, affected individuals had raised creatine
kinase levels.
Cases 8–11
Cases 8–11 are previously undescribed cases of GMPPB-
MDDG that were compared with CMS Cases 1–7. They
had previously been diagnosed with a muscular dystrophy,
and underlying mutations in GMPPB had separately been
identified. Cases 8, 9 and 10 are of Caucasian descent,
Case 11 is of Asian descent. Cases 9 and 10 are siblings.
There is no known consanguinity in any of the families.
Cases 8–11 presented in early childhood (1–2 years of
age). Case 8 presented with an episode of generalized
sudden weakness, Cases 9 and 10 presented with global
developmental delay (although for Case 9 it was initially
attributed to a preceding meningitis), and Case 11 pre-
sented with seizures. Cases 8, 9 and 11 have weakness in
proximal limb muscles, whereas Case 10 has no detectable
weakness. Case 8 has fluctuations of muscle strength with
infections, and Case 9 reports fatigability, particularly
noted when walking uphill. All have elevated creatine
kinase levels. Muscle biopsies were obtained from Cases
8, 9 and 11 and showed dystrophic features with reduced
-dystroglycan. Case 9 had a positive response to pyrido-
stigmine as shown by post-treatment muscle strength meas-
ures. The time for keeping his arms outstretched increased
from 23 to 102 s, and from 12 to 21 s in neck flexion. Of
note, from being initially unable to rise up from the floor
before treatment, he was able to rise to stand in 5.8 s.
Identification of mutations in GMPPB
as a cause of CMS
We performed whole exome sequencing of DNA from Case
1. The resulting data were filtered against the variants listed
on 1000 Genome Project, to remove all variants with popu-
lation frequency of 0.01 or more (Genomes Project et al.,
2010). We used ANNOVAR software to annotate and sep-
arate non-synonymous substitutions and splicing mutations
(Wang et al., 2010). As CMS is usually inherited in an
autosomal recessive manner, we focused on all genes that
have either one or more homozygous variant, or two or
more heterozygous variants in the same gene. We further
filtered the obtained variants against an in-house database
of 14 exomes from cases with unrelated disorders. This
analysis limited the list of possible candidate genes to
eight (Supplementary Table 1). The remaining variants
were ranked based on their functional annotation and pre-
dicted pathogenicity of associated mutations
(Supplementary Table 2). The most highly ranked candi-
date gene resulting from this analysis was GMPPB.
GMPPB encodes GDP-mannose pyrophosphorylase B—an
enzyme involved in glycosylation. Mutations in four other
glycosylation genes (ALG2, ALG14, DPAGT1 and
GFPT1) are known to lead to the development of CMS,
and the symptoms of other glycosylation-CMS patients are
similar to the symptoms of Case 1. Therefore, variants in
GMPPB were good candidates for a potential cause of
CMS. We found that Case 1 had two missense mutations
in GMPPB: p.Asp27His (c.79G4C) and p.Arg287Trp
(c.859C4T) (Table 1). Both mutations were confirmed by
Sanger sequencing.
The GMPPB gene has two isoforms NM_021971 and
NM_013334. NM_013334 has eight coding exons and
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387 amino acids, whereas NM_021971 has nine coding
exons and 360 amino acids. The first seven coding exons
of both isoforms are identical. The last eighth exon of
NM_013334 is 131 amino acids long. The middle 27
amino acids of the corresponding sequence are spliced
out in NM_021971 to produce exon 8 and exon 9. It
has previously been shown that isoform NM_021971 is
expressed in the skeletal muscle and the brain at much
higher levels than isoform NM_013334 (Carss et al.,
2013). Additionally, we did not find any variants in the
27 amino acids specific to isoform NM_013334 in any of
the cases described below. Therefore, we use RefSeq
NM_021971 for the annotation of all variants described
in this study.
We used Sanger sequencing to screen a cohort of sus-
pected CMS cases for the presence of further possible vari-
ants in the GMPPB gene. We identified six further cases
that had either two heterozygous mutations (Cases 2, 3 and
7) or a homozygous mutation (Cases 4, 5 and 6) in
GMPPB. Case 2 was compound heterozygote for
p.Arg261Cys (c.781C4T) and a potential splicing muta-
tion (c.130-3C4G), Case 3 carried p.Asp27His
Figure 2 Neurophysiological examination of Case 3 using repetitive nerve stimulation and concentric needle EMG. Repetitive
nerve stimulation studies performed on right anconeus muscle showed 50% amplitude decrement (A) in compound muscle action potentials
while there was no change in compound muscle action potential amplitude with repetitive stimulation of right abductor digiti minimi muscle (B).
Concentric needle EMG examination of the right biceps muscle at low force of contraction showed low amplitude, polyphasic motor unit action
potentials.
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(c.79G4C) and p.Val254Met (c.760G4A), Case 4 had a
homozygous p.Pro103Leu (c.308C4T) mutation, and Case
7 carried p.Asp27His (c.79G4C) and p.Leu303Phe
(c.907C4T). Case 4 came from a consanguineous family
and had two affected siblings (Cases 5 and 6) and four
unaffected siblings. Segregation analysis confirmed that
both affected siblings carried a homozygous (c.308C4T)
p.Pro103Leu mutation, while two unaffected siblings and
both parents carried only one copy of the allele (Fig. 3).
Similarly the GMPPB mutations segregated with disease on
all available family samples from Cases 1, 2, 3 and 7. Thus,
we identified seven cases of CMS with mutations in the
GMPPB gene. Three of the described mutations
(p.Asp27His, p.Arg287Trp, p.Arg287Gln) are listed in the
Exome Variant Server database ([Exome Variant Server,
NHLBI GO Exome Sequencing Project (ESP), Seattle, WA
(URL: http://evs.gs.washington.edu/EVS/) (Nov 2014)]).
The frequency of the mutations in the general population
are 0.077% (p.Asp27His), 0.008% (p.Arg287Trp), and
0.015% (p.Arg287Gln), consistent with the notion of the
variants being pathogenic.
Mutations in GMPPB can cause muscular dystrophy-dys-
troglycanopathy [MDDGA14 (MIM 615350), MDDGB14
(MIM 615351), MDDGC14 (MIM 615352)] (Carss et al.,
2013; Raphael et al., 2014). The clinical spectrum varies,
ranging from a relatively mild phenotype restricted to the
limb girdles, through congenital muscular dystrophy
with mental retardation, to severe congenital muscular
dystrophy with structural brain and eye defects. Serum
creatine kinase levels are elevated and analysis of muscle
biopsies from the affected individuals showed features char-
acteristic of a muscular dystrophy and reduction in the
amount of glycosylated -dystroglycan. EMG was not
performed.
Using Sanger sequencing muscular dystrophy Cases 8–11
were found to have mutations in GMPPB. Case 8 has
p.Gln187* and p.Ile193Thr, Cases 9 and 10 have
p.Ile219Thr and p.Arg287Gln, and Case 11 has
p.Pro22Ser and p.Asp334Asn mutations.
Thus, we identify GMPPB as a new gene locus in which
mutations can underlie a myasthenic syndrome. We also
describe four new MDDG patients due to mutations in
GMPPB.
Pathogenicity of GMPPB mutations
GMPPB encodes the enzyme mannose-1-phosphate guanyl-
transferase beta. It is a cytoplasmic protein that catalyses
the formation of GDP-mannose from mannose-1-phosphate
and GTP (Ning and Elbein, 2000; Davis et al., 2004).
GDP-mannose is used as a building block for multiple gly-
cosylation reactions including N- and O-linked glycosyla-
tion. Knockdown of a GMPPB orthologue in zebrafish
causes structural muscle and CNS and eye defects, with
reduced mobility and reduced glycosylation of -dystrogly-
can (Carss et al., 2013).
To confirm the pathogenicity of the newly identified mu-
tations, we performed a series of in silico and expression
level studies. Mutation c.130-3C4G alters the nucleotide
at the 3 position upstream of 3’ splice site of intron 2
(ENSEMBL transcript ID ENST00000480687). It is located
within the pyrimidine tract of the intron within a close
proximity of the splice acceptor site. Splice site prediction
software Human Splicing Finder v2.4.1 identified that this
mutation has the potential to disrupt the wild-type splice
site, altering the normal pre-mRNA splicing pattern
(Desmet et al., 2009). To test this prediction, we analysed
GMPPB RNA splicing using exon trapping. The exon trap
vector pET01 (MoBiTec) contains two exons separated by
an intron sequence containing a multiple cloning site
(Fig. 4). We cloned GMPPB exons 2, 3, 4 and flanking
intronic sequences into the pET01 vector, and introduced
the c.130-3C4G mutation by site-directed mutagenesis.
Results of the exon trap analysis are shown in Fig. 4.
The plasmid carrying wild-type sequence was correctly
spliced. The plasmid carrying c.130-3C4G mutation pro-
duced two products with different sizes: a larger transcript
in which exon 2 was skipped, and a shorter transcript in
Figure 3 Co-segregation of CMS phenotype with GMPPB mutations in one family (Cases 4–6). Pedigree symbols are shaded
according to the presence of clinical CMS symptoms.
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which both exon 2 and 3 were skipped. The deletion of
exon 2 would lead to the loss of the original start codon.
The alternative potential translation start site could be
either Met56 in exon 3 for the transcript lacking exon 2,
or Met77 in exon 4 for the transcript lacking exons 2 and
3. In either case the mutant transcript would lead to the
production of a truncated protein.
Human GMPPB contains an N-terminal pyrophosphory-
lase domain harbouring the conserved signature motif for
nucleotide binding and transfer, and a putative C-terminal
hexapeptide repeat domain expected to form a left-handed
beta helix structure (Fig. 5). Of the six CMS-causing mis-
sense mutations reported here, two (p.Asp27His,
p.Pro103Leu) reside in the N-terminal domain close to
the conserved sequence motif, and hence may have a
direct impact on catalysis. Both mutations were predicted
to be damaging by the CADD algorithm, and one mutation
(p.Asp27His) was predicted to be damaging by SIFT algo-
rithm (Ng and Henikoff, 2001; Kircher et al., 2014). The
other four mutations (Val254Met, p.Arg261Cys,
p.Arg287Trp, p.Leu303Phe) are found in the C-terminal
domain and may impact on other non-catalytic properties
of the protein (e.g. oligomerization, protein–protein inter-
actions) that remain to be determined. These four missense
mutations were predicted to be damaging by CADD and
SIFT algorithms, and three of them (Val254Met,
p.Arg287Trp, p.Leu303Phe) were predicted to be damaging
by PolyPhen-2 software (Adzhubei et al., 2010)
(Supplementary Table 3).
To determine the effect of the mutations on protein ex-
pression, we cloned and expressed wild-type and mutant
GMPPB in HEK293 cells. Endogenous levels of GMPPB
in HEK293 cells were too low to be detected on the west-
ern blot. The construct carrying wild-type GMPPB was well
expressed and easily detectable. Two of the newly found
mutations caused a drastic reduction of GMPPB expres-
sion: no expression was detectable for p.V254M (found
in Case 3) and p.R287W (found in Case 1) mutant con-
structs (Fig. 6A). Additionally, a clear reduction in expres-
sion of p.L303F (found in Case 7) was seen.
Figure 4 Mutation c.130-3C`G disrupts wild-type splicing pattern of GMPPB. (A) Schematic structure of GMPPB gene, the pET01
exon trap vector, and the exon trap vector with inserted GMPPB exons 2–4. (B) Gel electrophoresis of amplicons generated using vector-specific
primers. The wild-type (WT) construct generated one transcript, whereas c.130-3C4G mutant construct generates two shorter transcripts. (C)
Sequencing data and schematic diagrams showing aberrant splicing from the mutant construct. The nucleotide sequence around each splice site is
shown.
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In addition, we analysed expression and localization of
the mutant GMPPB in the mouse muscle C2C12 cell line.
In the majority of transfected cells wild-type GMPPB was
spread uniformly in the cytoplasm (Fig. 6B). In agreement
with the western blot results, expression of p.V254M and
p.R287W was drastically reduced, with only few cells ex-
pressing detectable level of protein. The cells that did ex-
press p.V254M or p.R287W displayed a punctate pattern
Figure 5 GMPPB domain structure and conservation. GMPPB is a 360-aa polypeptide and consists of nine exons (shown with blocks on
the scheme). It has two predicted PFAM domains: nucleotidyl transferase domain and bacterial transferase hexapeptide domain (shown with
yellow blocks). The scheme shows CMS-associated mutations (above GMPPB scheme), and mutations associated with muscular dystrophy
(underneath GMPPB scheme). Mutations described in this paper are shown in black, whereas mutations published previously are shown in grey
for comparison. Protein alignment was performed in ClustalW2.
Figure 6 Effect of different variants on GMPPB expression and localization. (A) GMPPB constructs were transfected into HEK293
cells, protein lysates were prepared 48 h after transfection and analysed by western blot using anti-GMPPB antibody. (B) GMPPB constructs were
transfected into C2C12 cells. Permeabilized cells were stained with anti-GMPPB antibody. Scale bar = 20 mm.
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of GMPPB localization, suggesting that these mutations
cause protein aggregation. Thus, some missense mutations
in GMPPB affect expression and localization, consistent
with the notion of the mutations being pathogenic. Other
missense mutations not impairing expression or localization
are likely to disrupt GMPPB catalytic activity or interaction
with potential partners.
Neuromuscular transmission defect
in patients harbouring GMPPB
mutations
The GMPPB-CMS cases described above have a clear
neurotransmission defect detectable on EMG studies
(Table 1 and Fig. 2). To determine whether all GMPPB
mutations lead to defective neuromuscular transmission
and whether the GMPPB-MDDG cases have myasthenic
features similar to CMS patients, we performed neuro-
physiological analysis of GMPPB-MDDG Cases 8–11.
Case 8, with heterozygous mutations in GMPPB
c.559C4T (p.Q187*) and c.578T4C (p.I193T), showed
a clear decrement on repetitive nerve stimulation. Minor
defects in neuromuscular junction transmission were also
observed in Cases 9 and 10 with an increase in jitter and
occasional block on SFEMG, although decrement was not
detected. By contrast, in Case 11 there was no evidence
from EMG or SFEMG of impaired neuromuscular trans-
mission, and no evidence of fatigable weakness on exam-
ination. These results demonstrate that some GMPPB
mutations may have a clear detrimental effect on neuro-
muscular transmission (in the case of CMS-associated mu-
tations, and a subset of MDDG-associated mutations),
while conversely others may have no detectable effect on
signal transmission at the neuromuscular junction (other
MDDG patients).
Myopathic features of GMPPB-CMS
Whereas a number of the CMS may show some non-
specific myopathic features on EMG or on muscle biopsy,
myopathic features seem to be an integral part of the
GMPPB-CMS. Analysed cases (Cases 1–5 and 7) have de-
finitive myopathic changes on concentric needle electro-
myography (for example see Fig. 2). All tested cases
(Cases 1–4 and 7) have elevated levels of serum creatine
kinase indicating muscle damage. Cases 1 and 3 have
undergone muscle biopsies and all showed dystrophic fea-
tures. Case 2 and 7 have undergone a muscle MRI study
and both showed selective muscle fibro-fatty replacement,
as observed in muscular dystrophies (Fig. 7).
The levels of -dystroglycan glycosylation in muscle biop-
sies can be assessed by immunohistochemistry using IIH6
antibody, which specifically recognizes the glycosylated iso-
form of the protein (Michele et al., 2002). This forms a
part of the diagnostic procedure for suspected muscular
dystrophy disorders and several GMPPB cases described
in this paper underwent such examinations. All analysed
cases (Cases 8, 9 and 11 for muscular dystrophy, and
Cases 3 and 7 for CMS) had reduced -dystroglycan
staining.
Thus, reduction in -dystroglycan glycosylation is
common to both disorders associated with GMPPB muta-
tions, and is likely to underlie the dystrophic features inte-
gral to both GMPPB-CMS and GMPPB-MDDG. However,
in cases of GMPPB-CMS, it is likely that additional neuro-
muscular junction proteins are mis-glycosylated, leading to
the defective synaptic transmission.
Discussion
We identify mutations in GMPPB, an enzyme involved in
glycosylation, as a new cause of CMS. GMPPB-CMS pa-
tients have hallmark myasthenic features—fluctuating
Figure 7 Muscle MRI from Case 2. The muscle MRI study (T1-
weighted sequences) showed consistent abnormalities in gluteal
(A), thigh (B) and calf (C) muscles, with confluent areas of
increased signal or end-stage appearance but relative sparing of
certain muscles, especially at the distal level, in keeping with the
clinical and electrophysiological findings.
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fatigable muscle weakness and decrement of compound
muscle action potential on repetitive nerve stimulation.
The CMS-associated GMPPB mutations that we describe
are predicted to be pathogenic by several different algo-
rithms, and several cause a distinct reduction in the ex-
pressed levels of the protein. Clinically, the GMPPB-CMS
cases identified (Cases 1–7) share many of the features that
are characteristic for other glycosylation-CMS subtypes
(ALG2-, ALG14-, DPAGT1- and GFPT1-CMS)
(Guergueltcheva et al., 2011; Cossins et al., 2013;
Zoltowska et al., 2013). The age of presentation of
GMPPB-CMS in adolescence or early adulthood seems
later than for most CMS. Muscle weakness is predomin-
antly limited to proximal muscle groups affecting both
lower and upper limbs. In common with other CMS due
to mutations affecting glycosylation, the facial, eye, and
bulbar muscles are largely spared. Ptosis was only present
in one of the newly-identified GMPPB-CMS cases, contrast-
ing with many other CMS subtypes where ptosis often
serves as an important clinical clue for considering CMS.
As in other glycosylation-pathway CMS, affected individ-
uals report a beneficial response to pyridostigmine or pyri-
dostigmine plus salbutamol.
GMPPB-associated muscular dystrophy cases show a re-
duction in the glycosylation level of -dystroglycan (Carss
et al., 2013). -Dystroglycan is an extracellular protein that
is non-covalently linked to the transmembrane b-dystrogly-
can (Holt et al., 2000). -Dystroglycan interacts with sev-
eral extracellular matrix components, while b-dystroglycan
interacts with intracellular cytoskeleton. Thus, the dystro-
glycan complex provides a link between the extracellular
matrix and intracellular machinery. Under normal condi-
tions, -dystroglycan is heavily O-glycosylated and this gly-
cosylation is essential for efficient interaction with its
extracellular partners (Michele et al., 2002; Michele and
Campbell, 2003). Reduction in the glycosylation level dis-
rupts these molecular interactions and contributes to desta-
bilization of the sarcolemma, contributing to muscle
damage during contraction. GMPPB-MDDG patients have
a set of characteristic dystrophic features and a variable
degree of structural brain and eye abnormalities. At the
severe end of the spectrum, mutations in GMPPB lead to
the congenital muscular dystrophy with brain and eye
abnormalities. At the mild end of the spectrum, mutations
in GMPPB lead to the limb-girdle muscular dystrophy that
is limited to a weakness in the proximal limb muscles.
Similar to GMPPB-MDDG, GMPPB-CMS have a set of
myopathic features that are detectable on muscle biopsies,
muscle MRI, concentric needle EMG, and through elevated
serum creatine kinase levels. Although several CMS sub-
types such as slow-channel syndrome (Chaouch et al.,
2012), DOK7-CMS (Mu¨ller et al., 2007) and GFPT1-
CMS (Guergueltcheva et al., 2011) can have mildly raised
creatine kinase values, this is rare (apart from in GFPT1-
CMS, not seen in over 300 CMS cases analysed in Oxford),
and when reported has rarely been more than two to three
times normal values. All the GMPPB-CMS patients have a
characteristic neuromuscular transmission defect that is de-
tectable by repetitive nerve stimulation EMG studies on the
affected group of muscles. A subset of GMPPB-MDDG pa-
tients display a neuromuscular transmission defect, whereas
other GMPPB-MDDG patients do not. Thus mutations in
GMPPB provide a link between myasthenic syndromes and
dystroglycanopathies. A relationship between CMS and
dystroglycanopathies has previously been proposed
(Compton et al., 2008); however, this was for a lethal
form of congenital myopathy due to mutations in
CNTN1 where affected individuals died at birth or shortly
afterwards. The wide spectrum of clinical features with
GMPPB mutations is likely due to its ubiquitous expres-
sion, and its involvement in the glycosylation of different
proteins. It is not clear at present why different mutations
in the same gene can lead to the different clinical
manifestations.
In summary, we identify mutations in GMPPB as a novel
genetic cause of impaired signal transmission at the neuro-
muscular junction. We find that mutations in GMPPB can
lead to overlapping phenotypes with a spectrum of different
clinical outcomes. At one end of the spectrum are cases in
which fatigable weakness with a characteristic neuromus-
cular junction transmission defect, is the major symptom,
at the other end mutations in GMPPB lead to the onset of
muscular dystrophy with no demonstrable effect on the
neuromuscular junction. CMS due to GMPPB mutations
may frequently remain undiagnosed due to lack of facial
features usually associated with myasthenia, the presence of
high creatine kinase levels and the restricted muscle groups
that show decrement on repetitive nerve stimulation.
Recognition of this condition is important as these patients
respond symptomatically to appropriate medication and
their quality of life can be significantly improved by appro-
priate treatment.
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